Curium to Acquire Radiopharmaceutical Peer Lantheus for Up to $8 Billion
Curium has agreed to acquire radiopharmaceutical company Lantheus Holdings in a deal valued at up to $8 billion. The transaction will see Lantheus shareholders receive $102.50 per share in cash, with the potential for an additional $12 per share if certain sales targets are met by 2030. This represents a total consideration of up to $114.50 per share, offering a premium of approximately 14.9% over Lantheus' last closing price. Lantheus CEO Mary Anne Heino praised the deal as validation of her company's seven decades of innovation in radiopharmaceuticals. The acquisition is expected to close following regulatory approvals and shareholder votes. Shares of Lantheus were halted in premarket trading ahead of the announcement.
Topics: Mergers & Acquisitions Pharmaceuticals Radiopharmaceuticals